Tracking invasive fungal infections after allogeneic hematopoietic stem cell transplant
Official title: Retrospective and Prospective Longitudinal Observational Study on Invasive Fungal Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Run by Peking University People's Hospital · NCT07569055 · Data updated 2026-11-12
We will follow people who had an allogeneic stem cell transplant to see how often serious fungal infections occur and which clinical factors predict them.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 6000 (estimated) |
| Sponsor | Peking University People's Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | March 15, 2025 |
| Main results expected | March 14, 2031 |
| Study ends | March 14, 2031 |
| Registry record updated | May 6, 2026 |
| Trial ID | NCT07569055 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients who underwent allogeneic HSCT at Peking University People's Hospital or the listed collaborating centers since January 1, 2014 and who can be followed for outcome data.
✕Probably not a fit
Patients who cannot provide reliable follow-up information (for example due to severe mental disorder or loss to follow-up) or who are deemed unsuitable by investigators may not benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a longitudinal cohort following patients who underwent allogeneic hematopoietic stem cell transplantation at Peking University People's Hospital and collaborating centers since January 1, 2014, to document occurrences of invasive fungal disease (IFD). Clinical data, diagnostic results, antifungal prevention and treatment regimens, pathogen types, and outcomes will be collected and analyzed over time. The project aims to describe changing epidemiology, compare pathogen spectra and clinical features, and identify prognostic factors associated with IFD and IFD-related mortality. Findings will be compared with prior multicenter data (such as CAESAR 2.0) to understand trends after changes in prevention and diagnostic practices.
Why it matters
Potential benefit: If successful, this work could help doctors identify transplant recipients at highest risk for invasive fungal infections and guide prevention and early treatment to reduce deaths and complications.
How similar studies have gone: Large cohort efforts such as CAESAR 2.0 have documented one-year incidence, high mortality, and shifts in pathogen patterns after allo-HSCT, but predictive models for individual risk remain limited, so this work builds on prior descriptive findings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Since January 1, 2014, patients who underwent allo-HSCT at Peking University People's Hospital and other assistance centers. Exclusion Criteria: 1. For any reason, such as the occurrence of severe mental disorders, the follow-up information may be unavailable; 2. Patients deemed unsuitable for the study by the researchers.
Where it's running
-
Peking University People's Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Xiao-Hui Zhang, MD — Peking University Institute of Hematology, Peking University People's Hospital
- Study coordinator: Jin Wu, MD
- Email: wujin1996@126.com
- Phone: 086-01088326002
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treating breakthrough invasive fungal infections in blood cancer patients with liposomal amphotericin B versus isavuconazole/posaconazole
This project will test whether liposomal amphotericin B or isavuconazole/posaconazole works better and is safer for adults with blood cancers who develop breakthrough invasive fungal infections after antifungal prophylaxis.
-
Ruxolitinib plus decitabine intensified conditioning for AML patients having allogeneic stem cell transplant
This trial will see if adding ruxolitinib and decitabine to standard busulfan-based conditioning before allogeneic HSCT lowers relapse in high‑risk AML patients in first complete remission (CR1).
-
Evaluating the effectiveness of amphotericin B and azoles for invasive fungal infections
This study looks at how well amphotericin B and azole antifungals work and how safe they are for patients with invasive fungal infections based on their medical records.
-
Immune monitoring during invasive mold infections.
This project will test whether tracking T-cell immune checkpoints can identify adults with invasive mold infections who might benefit from adding immunotherapy to antifungal treatment.
-
Detecting lung diseases early after stem cell transplants
This study is testing new ways to spot lung problems early in kids and adults who have had a stem cell transplant to help them get better treatment.
-
Global registry for emerging invasive fungal infections
This study is collecting information about invasive fungal infections to better understand how they spread, how they are diagnosed, and how well different treatments work for people affected by them.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.